XML 25 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)
 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2008
Glaxo, Smith, Kline
Project
Sep. 30, 2012
Glaxo, Smith, Kline
Sep. 30, 2011
Glaxo, Smith, Kline
Sep. 30, 2012
Glaxo, Smith, Kline
Sep. 30, 2011
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Sep. 30, 2006
Astra Zeneca
Sep. 30, 2012
Astra Zeneca
Sep. 30, 2012
Astra Zeneca
Dec. 31, 2008
Astra Zeneca
Dec. 31, 2011
Astra Zeneca
Oct. 31, 2011
Astra Zeneca
Amendment
Dec. 31, 2012
Astra Zeneca
Amendment
Mar. 31, 2012
Astra Zeneca
Amendment
Advance the program following completion of Phase 2a
May 31, 2012
National Institutes of Health
Fund Research
May 31, 2012
National Institutes of Health
Business Development
Jul. 31, 2012
National Institutes of Health
HBV
Jul. 31, 2011
National Institutes of Health
HPV
Sep. 30, 2008
National Institutes of Health
ISS Technology
Product Information [Line Items]                                              
Number of programs for research and early clinical development         4                                    
Collaboration revenue $ 1,050,000 $ 369,000 $ 3,602,000 $ 7,098,000 $ 10,000,000               $ 10,000,000     $ 3,000,000   $ 2,600,000          
Revenue from milestone payment             6,000,000   6,000,000 15,000,000   200,000 500,000 4,500,000       20,000,000          
Deferred revenue recognition period         7 years             5 years 5 years   5 years                
Revenue of deferred revenue           400,000 400,000 1,100,000 1,100,000                            
Deferred revenue           4,600,000   4,600,000   5,700,000   4,400,000 4,400,000   4,900,000                
Research collaboration and license agreement period                     3 years                        
Cost of clinical development activities                               20,000,000              
Development milestone payment                                 6,000,000            
Revenue from the performance of research services                       500,000 2,000,000                    
Contract agreement period                                             5 years
Contract awarded to develop technology                                             17,000,000
Percentage of contract NIAID is funding                                             100.00%
Grants receivable                                     $ 400,000 $ 600,000 $ 300,000 $ 600,000